KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Change in Cash: 2013-2024

Historic Change in Cash for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $69.4 million.

  • Palvella Therapeutics' Change in Cash rose 2442.84% to $69.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.3 million, marking a year-over-year increase of 976.16%. This contributed to the annual value of $76.3 million for FY2024, which is 976.16% up from last year.
  • As of Q4 2024, Palvella Therapeutics' Change in Cash stood at $69.4 million, which was up 21,128.79% from -$330,000 recorded in Q3 2024.
  • In the past 5 years, Palvella Therapeutics' Change in Cash ranged from a high of $69.4 million in Q4 2024 and a low of -$34.0 million during Q1 2022.
  • For the 3-year period, Palvella Therapeutics' Change in Cash averaged around -$965,000, with its median value being -$2.0 million (2023).
  • In the last 5 years, Palvella Therapeutics' Change in Cash crashed by 844.93% in 2022 and then spiked by 2,442.84% in 2024.
  • Palvella Therapeutics' Change in Cash (Quarterly) stood at $3.5 million in 2020, then plummeted by 305.53% to -$7.3 million in 2021, then plummeted by 34.30% to -$9.8 million in 2022, then surged by 69.74% to -$3.0 million in 2023, then surged by 2,442.84% to $69.4 million in 2024.
  • Its last three reported values are $69.4 million in Q4 2024, -$330,000 for Q3 2024, and $8.3 million during Q2 2024.